Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Taysha Gene Therapies Inc’s stock clocked out at $1.77, up 6.63% from its previous closing price of $1.66. In other words, the price has increased by $6.63 from its previous closing price. On the day, 1.67 million shares were traded. TSHA stock price reached its highest trading level at $1.78 during the session, while it also had its lowest trading level at $1.63.
Ratios:
To gain a deeper understanding of TSHA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.89 whereas as Long-Term Debt/Eq ratio is at 0.86.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on June 27, 2024, initiated with a Outperform rating and assigned the stock a target price of $5.
On April 09, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $9.
Jefferies Downgraded its Buy to Hold on February 01, 2023, whereas the target price for the stock was revised from $14 to $1.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 27 ’24 when Manning Paul B bought 1,333,333 shares for $2.25 per share. The transaction valued at 2,999,999 led to the insider holds 1,333,333 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 362853536 and an Enterprise Value of 287375904. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.56 while its Price-to-Book (P/B) ratio in mrq is 5.07. Its current Enterprise Value per Revenue stands at 34.486 whereas that against EBITDA is -3.366.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.87, which has changed by -0.44164038 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $4.32, while it has fallen to a 52-week low of $1.19. The 50-Day Moving Average of the stock is 7.97%, while the 200-Day Moving Average is calculated to be -15.38%.
Shares Statistics:
It appears that TSHA traded 1.96M shares on average per day over the past three months and 1788990 shares per day over the past ten days. A total of 204.94M shares are outstanding, with a floating share count of 165.01M. Insiders hold about 19.51% of the company’s shares, while institutions hold 77.27% stake in the company. Shares short for TSHA as of 1740700800 were 25530638 with a Short Ratio of 13.02, compared to 1738281600 on 24081792. Therefore, it implies a Short% of Shares Outstanding of 25530638 and a Short% of Float of 16.430001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Taysha Gene Therapies Inc (TSHA) is currently being evaluated by 2.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.38 and -$0.38 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.41, with 1.0 analysts recommending between -$0.41 and -$0.41.
